Humacyte, Inc. (HUMA)
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection.
The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes.
The company was founded in 2004 and is headquartered in Durham, North Carolina.
2525 East North Carolina Highway 54
Durham, NC 27713
|Phone||919 313 9633|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Dr. Laura E. Niklason M.D., Ph.D.||Founder, President, Chief Executive Officer and Director|
|Dale A. Sander||Chief Financial Officer, Chief Corporate Development Officer and Treasurer|
|Dr. Heather Ledbetter Prichard Ph.D.||Chief Operating Officer|
|Dr. Juliana L. Blum Ph.D.||Co-Founder and Executive Vice President of Corporate Development|
|Sabrina Osborne||Executive Vice President of Business Strategy and People|
|William Edward Tente M.S, M.S.||Chief Regulatory Officer|
|William Scheessele||Chief Commercial Officer|
|Dr. Shamik J. Parikh M.D.||Chief Medical Officer|
Latest SEC Filings
|May 18, 2022||4||Statement of changes in beneficial ownership of securities|
|May 13, 2022||424B3||Prospectus [Rule 424(b)(3)]|
|May 13, 2022||10-Q||Quarterly report [Sections 13 or 15(d)]|
|May 13, 2022||8-K||Current report|
|Apr 29, 2022||DEFA14A||Additional definitive proxy soliciting materials and Rule 14(a)(12) material|
|Apr 29, 2022||DEF 14A||Other definitive proxy statements|
|Apr 5, 2022||4||Statement of changes in beneficial ownership of securities|
|Apr 5, 2022||3||Initial statement of beneficial ownership of securities|
|Apr 4, 2022||424B7||Prospectus [Rule 424(b)(7)]|
|Apr 1, 2022||EFFECT||Notice of Effectiveness|
|View All SEC Filings|